| Date Filed | Type | Description |
| 10/11/2023 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements: |
| 10/11/2023 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
| 10/10/2023 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 10/10/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 5% stake in Intercept Pharmaceuticals Inc. |
| 10/10/2023 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
| 09/28/2023 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
| 09/26/2023 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
| 08/03/2023 |
4
| Freedberg Jared (General Counsel) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 771 shares
@ $10.5, valued at
$8.1k
|
|
| 08/02/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/02/2023 |
8-K
| Quarterly results |
| 07/10/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 11.3% stake in Intercept Pharmaceuticals Inc. |
| 07/07/2023 |
SC 13G/A
| BlackRock Inc. reports a 10.5% stake in INTERCEPT PHARMACEUTICALS, INC. |
| 06/16/2023 |
4
| Berrey M Michelle (President, R&D & CMO) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 1,246 shares
@ $12.04, valued at
$15k
|
|
| 05/25/2023 |
4
| Benatti Luca (Director) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.|
Txns:
| Granted 8,111 shares
@ $0
Granted 12,547 options to buy
@ $9.17, valued at
$115.1k
|
|
| 05/25/2023 |
4
| SBLENDORIO GLENN (Director) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.|
Txns:
| Granted 8,111 shares
@ $0
Granted 12,547 options to buy
@ $9.17, valued at
$115.1k
|
|
| 05/25/2023 |
4
| Gottesdiener Keith Michael (Director) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.|
Txns:
| Granted 8,111 shares
@ $0
Granted 12,547 options to buy
@ $9.17, valued at
$115.1k
|
|
| 05/25/2023 |
4
| Fundaro Paolo (Director) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.|
Txns:
| Granted 8,111 shares
@ $0
Granted 12,547 options to buy
@ $9.17, valued at
$115.1k
|
|
| 05/25/2023 |
4
| SANTINI GINO (Director) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.|
Txns:
| Granted 8,111 shares
@ $0
Granted 12,547 options to buy
@ $9.17, valued at
$115.1k
|
|
| 05/25/2023 |
4
| ROSA-BJORKESON DAGMAR (Director) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.|
Txns:
| Granted 8,111 shares
@ $0
Granted 12,547 options to buy
@ $9.17, valued at
$115.1k
|
|
| 05/25/2023 |
4
| Miller-Rich Nancy (Director) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.|
Txns:
| Granted 8,111 shares
@ $0
Granted 12,547 options to buy
@ $9.17, valued at
$115.1k
|
|
| 05/25/2023 |
4
| BRADBURY DANIEL (Director) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.|
Txns:
| Granted 8,111 shares
@ $0
Granted 12,547 options to buy
@ $9.17, valued at
$115.1k
|
|
| 05/25/2023 |
4
| AKKARAJU SRINIVAS (Director) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.|
Txns:
| Granted 8,111 shares
@ $0
Granted 12,547 options to buy
@ $9.17, valued at
$115.1k
|
|
| 05/25/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/01/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/01/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/27/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/27/2023 |
8-K
| Quarterly results |
| 03/24/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 03/24/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 03/24/2023 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
| 03/23/2023 |
4
| Saik Andrew (EVP & CFO) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 909 shares
@ $14.19, valued at
$12.9k
|
|
| 03/16/2023 |
4
| Berrey M Michelle (President, R&D & CMO) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 1,246 shares
@ $15.79, valued at
$19.7k
|
|
| 03/02/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/02/2023 |
8-K
| Quarterly results |
|